# Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

> **NCT02345226** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 881 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** FTC/RPV/TAF
- **DRUG:** EFV/FTC/TDF Placebo
- **DRUG:** EFV/FTC/TDF
- **DRUG:** FTC/RPV/TAF Placebo

## Key facts

- **NCT ID:** NCT02345226
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-26
- **Primary completion:** 2016-06-29
- **Final completion:** 2019-01-02
- **Target enrollment:** 881 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345226, "Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02345226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*